Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases
• Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months.
Gespeichert in:
| Autor*in: |
Palmer, Joshua D. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:170 ; year:2022 ; pages:21-26 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.radonc.2022.03.016 |
|---|
| Katalog-ID: |
ELV057671133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV057671133 | ||
| 003 | DE-627 | ||
| 005 | 20230625002728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2022.03.016 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica |
| 035 | |a (DE-627)ELV057671133 | ||
| 035 | |a (ELSEVIER)S0167-8140(22)00154-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Palmer, Joshua D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases |
| 264 | 1 | |c 2022 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. | ||
| 650 | 7 | |a CTCAE |2 Elsevier | |
| 650 | 7 | |a RT |2 Elsevier | |
| 650 | 7 | |a PR |2 Elsevier | |
| 650 | 7 | |a RECIST |2 Elsevier | |
| 650 | 7 | |a AE |2 Elsevier | |
| 650 | 7 | |a OS |2 Elsevier | |
| 650 | 7 | |a WBRT |2 Elsevier | |
| 650 | 7 | |a MRI |2 Elsevier | |
| 650 | 7 | |a G |2 Elsevier | |
| 650 | 7 | |a BM |2 Elsevier | |
| 650 | 7 | |a DLT |2 Elsevier | |
| 650 | 7 | |a ORR |2 Elsevier | |
| 650 | 7 | |a CR |2 Elsevier | |
| 650 | 7 | |a CT |2 Elsevier | |
| 650 | 7 | |a SD |2 Elsevier | |
| 650 | 7 | |a MEK |2 Elsevier | |
| 650 | 7 | |a SRT |2 Elsevier | |
| 650 | 7 | |a PD |2 Elsevier | |
| 650 | 7 | |a SRS |2 Elsevier | |
| 650 | 7 | |a ECOG |2 Elsevier | |
| 650 | 7 | |a LC |2 Elsevier | |
| 650 | 7 | |a MTD |2 Elsevier | |
| 650 | 7 | |a nPFS |2 Elsevier | |
| 700 | 1 | |a Prasad, Rahul N. |4 oth | |
| 700 | 1 | |a Fabian, Denise |4 oth | |
| 700 | 1 | |a Wei, Lai |4 oth | |
| 700 | 1 | |a Yildiz, Vedat O. |4 oth | |
| 700 | 1 | |a Tan, Yubo |4 oth | |
| 700 | 1 | |a Grecula, John |4 oth | |
| 700 | 1 | |a Welliver, Meng |4 oth | |
| 700 | 1 | |a Williams, Terence |4 oth | |
| 700 | 1 | |a Elder, James B. |4 oth | |
| 700 | 1 | |a Raval, Raju |4 oth | |
| 700 | 1 | |a Blakaj, Dukagjin |4 oth | |
| 700 | 1 | |a Haglund, Karl |4 oth | |
| 700 | 1 | |a Bazan, Jose |4 oth | |
| 700 | 1 | |a Kendra, Kari |4 oth | |
| 700 | 1 | |a Arnett, Andrea |4 oth | |
| 700 | 1 | |a Beyer, Sasha |4 oth | |
| 700 | 1 | |a Liebner, David |4 oth | |
| 700 | 1 | |a Giglio, Pierre |4 oth | |
| 700 | 1 | |a Puduvalli, Vinay |4 oth | |
| 700 | 1 | |a Chakravarti, Arnab |4 oth | |
| 700 | 1 | |a Wuthrick, Evan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
| 773 | 1 | 8 | |g volume:170 |g year:2022 |g pages:21-26 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2022.03.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 170 |j 2022 |h 21-26 |g 6 | ||
| author_variant |
j d p jd jdp |
|---|---|
| matchkey_str |
palmerjoshuadprasadrahulnfabiandenisewei:2022----:hsitdotaeiiicmiainihhlbanaitote |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1016/j.radonc.2022.03.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica (DE-627)ELV057671133 (ELSEVIER)S0167-8140(22)00154-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Palmer, Joshua D. verfasserin aut Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases 2022 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Elsevier Prasad, Rahul N. oth Fabian, Denise oth Wei, Lai oth Yildiz, Vedat O. oth Tan, Yubo oth Grecula, John oth Welliver, Meng oth Williams, Terence oth Elder, James B. oth Raval, Raju oth Blakaj, Dukagjin oth Haglund, Karl oth Bazan, Jose oth Kendra, Kari oth Arnett, Andrea oth Beyer, Sasha oth Liebner, David oth Giglio, Pierre oth Puduvalli, Vinay oth Chakravarti, Arnab oth Wuthrick, Evan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:170 year:2022 pages:21-26 extent:6 https://doi.org/10.1016/j.radonc.2022.03.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 170 2022 21-26 6 |
| spelling |
10.1016/j.radonc.2022.03.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica (DE-627)ELV057671133 (ELSEVIER)S0167-8140(22)00154-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Palmer, Joshua D. verfasserin aut Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases 2022 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Elsevier Prasad, Rahul N. oth Fabian, Denise oth Wei, Lai oth Yildiz, Vedat O. oth Tan, Yubo oth Grecula, John oth Welliver, Meng oth Williams, Terence oth Elder, James B. oth Raval, Raju oth Blakaj, Dukagjin oth Haglund, Karl oth Bazan, Jose oth Kendra, Kari oth Arnett, Andrea oth Beyer, Sasha oth Liebner, David oth Giglio, Pierre oth Puduvalli, Vinay oth Chakravarti, Arnab oth Wuthrick, Evan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:170 year:2022 pages:21-26 extent:6 https://doi.org/10.1016/j.radonc.2022.03.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 170 2022 21-26 6 |
| allfields_unstemmed |
10.1016/j.radonc.2022.03.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica (DE-627)ELV057671133 (ELSEVIER)S0167-8140(22)00154-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Palmer, Joshua D. verfasserin aut Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases 2022 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Elsevier Prasad, Rahul N. oth Fabian, Denise oth Wei, Lai oth Yildiz, Vedat O. oth Tan, Yubo oth Grecula, John oth Welliver, Meng oth Williams, Terence oth Elder, James B. oth Raval, Raju oth Blakaj, Dukagjin oth Haglund, Karl oth Bazan, Jose oth Kendra, Kari oth Arnett, Andrea oth Beyer, Sasha oth Liebner, David oth Giglio, Pierre oth Puduvalli, Vinay oth Chakravarti, Arnab oth Wuthrick, Evan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:170 year:2022 pages:21-26 extent:6 https://doi.org/10.1016/j.radonc.2022.03.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 170 2022 21-26 6 |
| allfieldsGer |
10.1016/j.radonc.2022.03.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica (DE-627)ELV057671133 (ELSEVIER)S0167-8140(22)00154-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Palmer, Joshua D. verfasserin aut Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases 2022 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Elsevier Prasad, Rahul N. oth Fabian, Denise oth Wei, Lai oth Yildiz, Vedat O. oth Tan, Yubo oth Grecula, John oth Welliver, Meng oth Williams, Terence oth Elder, James B. oth Raval, Raju oth Blakaj, Dukagjin oth Haglund, Karl oth Bazan, Jose oth Kendra, Kari oth Arnett, Andrea oth Beyer, Sasha oth Liebner, David oth Giglio, Pierre oth Puduvalli, Vinay oth Chakravarti, Arnab oth Wuthrick, Evan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:170 year:2022 pages:21-26 extent:6 https://doi.org/10.1016/j.radonc.2022.03.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 170 2022 21-26 6 |
| allfieldsSound |
10.1016/j.radonc.2022.03.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica (DE-627)ELV057671133 (ELSEVIER)S0167-8140(22)00154-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Palmer, Joshua D. verfasserin aut Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases 2022 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Elsevier Prasad, Rahul N. oth Fabian, Denise oth Wei, Lai oth Yildiz, Vedat O. oth Tan, Yubo oth Grecula, John oth Welliver, Meng oth Williams, Terence oth Elder, James B. oth Raval, Raju oth Blakaj, Dukagjin oth Haglund, Karl oth Bazan, Jose oth Kendra, Kari oth Arnett, Andrea oth Beyer, Sasha oth Liebner, David oth Giglio, Pierre oth Puduvalli, Vinay oth Chakravarti, Arnab oth Wuthrick, Evan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:170 year:2022 pages:21-26 extent:6 https://doi.org/10.1016/j.radonc.2022.03.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 170 2022 21-26 6 |
| language |
English |
| source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:170 year:2022 pages:21-26 extent:6 |
| sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:170 year:2022 pages:21-26 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
CTCAE RT PR RECIST AE OS WBRT MRI G BM DLT ORR CR CT SD MEK SRT PD SRS ECOG LC MTD nPFS |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| authorswithroles_txt_mv |
Palmer, Joshua D. @@aut@@ Prasad, Rahul N. @@oth@@ Fabian, Denise @@oth@@ Wei, Lai @@oth@@ Yildiz, Vedat O. @@oth@@ Tan, Yubo @@oth@@ Grecula, John @@oth@@ Welliver, Meng @@oth@@ Williams, Terence @@oth@@ Elder, James B. @@oth@@ Raval, Raju @@oth@@ Blakaj, Dukagjin @@oth@@ Haglund, Karl @@oth@@ Bazan, Jose @@oth@@ Kendra, Kari @@oth@@ Arnett, Andrea @@oth@@ Beyer, Sasha @@oth@@ Liebner, David @@oth@@ Giglio, Pierre @@oth@@ Puduvalli, Vinay @@oth@@ Chakravarti, Arnab @@oth@@ Wuthrick, Evan @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00004122X |
| dewey-sort |
3570 |
| id |
ELV057671133 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057671133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625002728.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2022.03.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057671133</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(22)00154-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Palmer, Joshua D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTCAE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RECIST</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WBRT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MRI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">G</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DLT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEK</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SRT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SRS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ECOG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MTD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">nPFS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prasad, Rahul N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabian, Denise</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wei, Lai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yildiz, Vedat O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tan, Yubo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grecula, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Welliver, Meng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams, Terence</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elder, James B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raval, Raju</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blakaj, Dukagjin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haglund, Karl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bazan, Jose</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kendra, Kari</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnett, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beyer, Sasha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liebner, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giglio, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Puduvalli, Vinay</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chakravarti, Arnab</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wuthrick, Evan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:170</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:21-26</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2022.03.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">170</subfield><subfield code="j">2022</subfield><subfield code="h">21-26</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| author |
Palmer, Joshua D. |
| spellingShingle |
Palmer, Joshua D. ddc 570 Elsevier CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases |
| authorStr |
Palmer, Joshua D. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 540 VZ Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS Elsevier |
| topic |
ddc 570 Elsevier CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS |
| topic_unstemmed |
ddc 570 Elsevier CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS |
| topic_browse |
ddc 570 Elsevier CTCAE Elsevier RT Elsevier PR Elsevier RECIST Elsevier AE Elsevier OS Elsevier WBRT Elsevier MRI Elsevier G Elsevier BM Elsevier DLT Elsevier ORR Elsevier CR Elsevier CT Elsevier SD Elsevier MEK Elsevier SRT Elsevier PD Elsevier SRS Elsevier ECOG Elsevier LC Elsevier MTD Elsevier nPFS |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r n p rn rnp d f df l w lw v o y vo voy y t yt j g jg m w mw t w tw j b e jb jbe r r rr d b db k h kh j b jb k k kk a a aa s b sb d l dl p g pg v p vp a c ac e w ew |
| hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| hierarchy_parent_id |
ELV00004122X |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00004122X |
| title |
Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases |
| ctrlnum |
(DE-627)ELV057671133 (ELSEVIER)S0167-8140(22)00154-2 |
| title_full |
Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases |
| author_sort |
Palmer, Joshua D. |
| journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
21 |
| author_browse |
Palmer, Joshua D. |
| container_volume |
170 |
| physical |
6 |
| class |
570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Palmer, Joshua D. |
| doi_str_mv |
10.1016/j.radonc.2022.03.016 |
| dewey-full |
570 540 |
| title_sort |
phase i study of trametinib in combination with whole brain radiation therapy for brain metastases |
| title_auth |
Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases |
| abstract |
• Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. |
| abstractGer |
• Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. |
| abstract_unstemmed |
• Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases |
| url |
https://doi.org/10.1016/j.radonc.2022.03.016 |
| remote_bool |
true |
| author2 |
Prasad, Rahul N. Fabian, Denise Wei, Lai Yildiz, Vedat O. Tan, Yubo Grecula, John Welliver, Meng Williams, Terence Elder, James B. Raval, Raju Blakaj, Dukagjin Haglund, Karl Bazan, Jose Kendra, Kari Arnett, Andrea Beyer, Sasha Liebner, David Giglio, Pierre Puduvalli, Vinay Chakravarti, Arnab Wuthrick, Evan |
| author2Str |
Prasad, Rahul N. Fabian, Denise Wei, Lai Yildiz, Vedat O. Tan, Yubo Grecula, John Welliver, Meng Williams, Terence Elder, James B. Raval, Raju Blakaj, Dukagjin Haglund, Karl Bazan, Jose Kendra, Kari Arnett, Andrea Beyer, Sasha Liebner, David Giglio, Pierre Puduvalli, Vinay Chakravarti, Arnab Wuthrick, Evan |
| ppnlink |
ELV00004122X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.radonc.2022.03.016 |
| up_date |
2024-07-06T16:49:29.281Z |
| _version_ |
1803849112519442432 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057671133</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625002728.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2022.03.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001797.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057671133</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(22)00154-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Palmer, Joshua D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Trametinib is a MEK inhibitor with intracranial activity used for BRAF+ disease. • Even subtherapeutic trametinib doses are toxic with whole brain radiation therapy. • The overall response rate was 33% with a median survival of 2.2 months.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTCAE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RECIST</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WBRT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MRI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">G</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DLT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEK</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SRT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SRS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ECOG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">LC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MTD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">nPFS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prasad, Rahul N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabian, Denise</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wei, Lai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yildiz, Vedat O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tan, Yubo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grecula, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Welliver, Meng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams, Terence</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elder, James B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raval, Raju</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blakaj, Dukagjin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haglund, Karl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bazan, Jose</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kendra, Kari</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnett, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beyer, Sasha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liebner, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giglio, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Puduvalli, Vinay</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chakravarti, Arnab</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wuthrick, Evan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:170</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:21-26</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2022.03.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">170</subfield><subfield code="j">2022</subfield><subfield code="h">21-26</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.3990517 |